Biotheranostics (Biotheranostics, we or us), is committed to protecting the privacy of all visitors to the BreastCancerIndex.com website. Biotheranostics has established this privacy statement to inform you of the specific practices and guidelines that help ensure the security and confidentiality of your personal information.
Biotheranostics may revise this privacy statement from time to time. All updates to this statement will be posted on this web page. If we make significant changes, Biotheranostics will notify you by posting a notice on the website. Please check the website for the most current version of our privacy statement. Your continued use of the website after we have posted a notice on the website constitutes your acceptance of such changes.
Linked web sites
BreastCancerIndex.com may contain links to external websites. Biotheranostics does not maintain these sites and is not responsible for the privacy practices of sites that it does not operate. Please refer to the specific privacy statements posted on these sites.
Aggregate data collection
Biotheranostics tracks visits to our website and uses visitor logs to compile anonymous aggregate statistics. We collect information such as the total number of visitors, pages visited, search terms, IP addresses, browsers, computer platforms, and domain names.
Certain pages of the website and/or html e-mail correspondence may use session cookies, persistent cookies, or web beacons to anonymously track unique visitors, save website preferences, or allow us to recognize visits from the same computer and browser. You have the option to reject the websites cookies and still use the website. However, your access to the website may be limited.
Types of personal information collected
Biotheranostics may collect, store, and use personally identifiable information (such as name, e-mail address, postal code, and e-mail preferences) when it is voluntarily submitted to us, such as when you register for information or contact us.
BreastCancerIndex.com is directed toward adults and does not knowingly collect information from children under the age of 13.
Use of personal information
We may use your personal information to contact you, improve this site, provide you with information that you have requested, or provide you with additional information which Biotheranostics believes may be of interest to you. We may also use this information to respond to your inquiries, provide you with technical support, and enforce our Terms and Conditions and other policies governing use of the website. We may combine your information with other information about you that is available to us, including information from other sources.
Biotheranostics will not sell or rent your personal information to any other company or organization. Biotheranostics may share your information with third party service providers who perform marketing or other services on our behalf. Biotheranostics may access and/or disclose your personal information to law enforcement officials, regulatory agencies or other third parties as we, in our sole discretion, believe necessary or appropriate in connection with an investigation of illegal activity that may expose us to legal liability, to enforce our policies governing the website and for regulatory compliance. Biotheranostics may also disclose your information connection with corporate restructuring, merger or consolidation with, or sale of substantially all of our assets to, a third party, as long as the third party agrees to abide by this privacy statement.
If you have questions about this privacy statement, please contact us firstname.lastname@example.org
The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.
This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.